The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement



Amicus Therapeutics Inc (FOLD)

Amicus Therapeutics is a biotechnology company focused on discovering, developing, and delivering medicines for diseases. Co.'s gene therapy portfolio pipeline include Pompe disease, Fabry disease, CDKL5 deficiency disorder, ceroid lipofuscinosis, neuronal, Mucopolysaccharidosis Type IIIB, as well as a program in Mucopolysaccharidosis Type IIIA. Co.'s collaboration with University of Pennsylvania also provides Co. with disease-specific access and option rights to develop new gene therapy platform technologies and programs for most lysosomal disorders and a portfolio of other rare diseases.

FOLD SEC Filing Email Alerts Service

FOLD — Key Stats (updated 4 hours, 29 minutes ago)
Company Name:  Amicus Therapeutics Inc
Website:  www.amicusrx.com
Sector:  Biotechnology
Number of ETFs Holding FOLD:  33
Total Market Value Held by ETFs:  $457.95M
Total Market Capitalization:  $3.12B
% of Market Cap. Held by ETFs:  14.68%
FOLD — News
FOLD — Price Chart
April 19, 2024  •  3:14 PM Eastern
Latest Market News Video


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
FOLD — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree FOLD Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Strong Buy (3.60 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
FOLD Stock Forecast

 Based on Zacks ABR data;
powered by Xignite
FOLD — Performance

Amicus Therapeutics Inc (FOLD) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.